Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RAD51C R237* |
Therapy | Cisplatin + Fluorouracil + Trastuzumab |
Indication/Tumor Type | gastroesophageal adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RAD51C R237* | gastroesophageal adenocarcinoma | predicted - sensitive | Cisplatin + Fluorouracil + Trastuzumab | Case Reports/Case Series | Actionable | In a retrospective analysis, treatment with the combination of Herceptin (trastuzumab), Platinol (cisplatin), and Adrucil (fluorouracil) resulted in a partial response and a progression-free survival of 13.0 months in a patient with gastroesophageal adenocarcinoma harboring RAD51C R237* (PMID: 37129948). | 37129948 |
PubMed Id | Reference Title | Details |
---|---|---|
(37129948) | BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. | Full reference... |